Eli Lilly Reports Stellar Q1 Performance

In an impressive display of growth, Eli Lilly announced a 45% surge in its first-quarter revenue for fiscal 2025, reaching $12.73 billion. This remarkable achievement was primarily driven by the increasing demand for its groundbreaking weight-loss and diabetes medications, Mounjaro and Zepbound.

Financial Highlights and Future Outlook

The company also revealed a net income of $2.76 billion for the quarter, marking a 23% increase compared to the previous year. Despite facing $1.57 billion in acquired in-process R&D charges, earnings per share stood strong at $3.06.

CEO David Ricks shared exciting updates on the company's oral GLP-1 candidate, forgilzumab, and confidently reaffirmed the annual revenue guidance, projecting between $58 billion and $61 billion. In response to the soaring demand, Lilly unveiled ambitious plans for a $50 billion expansion of its US manufacturing capabilities.